Professor Jack Price, Head of Advanced Therapies at NIBSC comments:
"The next stage of our work intends to improve the characterisation of existing EUTCD-grade cell lines to create a unique and highly valuable resource to SMEs or academics seeking to develop a stem cell based therapy, particularly within the European market."
"By demonstrating that our stem cell lines are vCJD-free and performing more comprehensive cancer panel screening and genome sequencing, we hope to enhance their utility worldwide."
"By demonstrating that our stem cell lines are vCJD-free and performing more comprehensive cancer panel screening and genome sequencing, we hope to enhance their utility worldwide."
Professor Jack Price, Head of Advanced Therapies at NIBSC
"Continuing to develop our relationship with academic, SME and pharmaceutical companies is a key part of our future plans. We hope to create an Advanced Therapies Industry forum to encourage engagement and collaboration between key academic, industry and regulatory partners and drive activity in regenerative medicine."
More about the UK Stem Cell Bank
Jointly funded by the Medical Research Council (MRC) and BBSRC (Biotechnology and Biological Sciences Research Council), the UK Stem Cell Bank was established in 2002 to store, characterise and supply ethically approved, quality controlled stem cell lines that could be using in medical research and clinical applications.
For information on the UKSCB visit the webpage or contact the team at enquiries@ukstemcellbank.org.uk